logo

For the Inventor, By the Inventor

Berlin, Germany

Thomas Rudel

This inventor holds 7 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignees: Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E. V. , Aeterna Zentaris Gmbh, Other. Active years: 2001-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Thomas Rudel. Retrieved from https://idiyas.com/inventor/thomas-rudel

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 

% Patents Active = 28.6


Average Co-Inventor Count = 4.2

ph-index = 2

Forward Citations = 43(Granted Patents)


Location History:

  • Tübingen, DE (2001)
  • La Jolla, CA (US) (2003 - 2012)
  • Berlin, DE (2006 - 2014)

Company Filing History:

goldMedal5 out of 1,335 
 
Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E. V.
 patents
silverMedal1 out of 36 
 
Aeterna Zentaris Gmbh
 patents
bronzeMedal1 out of 834,570 
Other
 patents

Years Active: 2001-2014

Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents
1. 8784813 - [object Object] (2014-07-22),
2. 8658615 - Prohibitin as target for cancer therapy (2014-02-25),
3. 8114971 - [object Object] (2012-02-14),
4. 7407784 - [object Object] (2008-08-05),
5. 7074889 - [object Object] (2006-07-11),
6. 6617128 - Nucleic acid molecules encoding proteins which impart the adhesion of neisseria cells to human cells (2003-09-09),
7. 6268171 - Recombinant PilC proteins, methods for producing them and their use (2001-07-31),

Title: Thomas Rudel: Innovator in Cancer Therapy

Introduction

Thomas Rudel is a prominent inventor based in Berlin, Germany. He has made significant contributions to the field of cancer therapy through his innovative research and development. With a total of 7 patents, Rudel's work focuses on cytotoxic polypeptides and pharmaceutical compositions aimed at treating hyperproliferative disorders.

Latest Patents

Rudel's latest patents include a cytotoxic polypeptide that is an L-amino acid oxidase isolated from the ink of the sea hare. This invention serves as a target for cancer therapy. Additionally, he has developed pharmaceutical compositions that comprise inhibitors of Prohibitin (PHB) for the prevention and treatment of hyperproliferative disorders.

Career Highlights

Throughout his career, Thomas Rudel has worked with esteemed organizations, including the Max Planck Society for the Advancement of Science. His research has been pivotal in advancing therapeutic options for cancer patients.

Collaborations

Rudel has collaborated with notable individuals in his field, including Thomas F. Meyer and Daniel Butzke. These partnerships have further enhanced the impact of his research and innovations.

Conclusion

Thomas Rudel's contributions to cancer therapy through his patents and collaborations highlight his role as a key innovator in the field. His work continues to inspire advancements in medical research and treatment options.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…